Researchers reviewed how a compound called Total glucosides of paeony (TGP) might affect liver cirrhosis. This review focused on how TGP interacts with the gut-liver axis to potentially improve liver health. The findings are based primarily on preclinical data, which means the research was conducted in laboratory settings rather than in human clinical trials.
In these early studies, TGP was linked to a more balanced gut microbiome and the strengthening of proteins that protect the intestinal barrier. These changes may help reduce the movement of harmful bacteria and toxins into the liver. The study also noted that TGP might activate specific pathways to reduce inflammation and normalize bile acid levels.
Because these results come from preclinical studies, the evidence is currently not enough to confirm how TGP works in humans. More clinical trials are needed to determine if these effects are safe and effective for people with liver cirrhosis. Patients should speak with their doctors before considering any new supplements or treatments.
